Trendlines' Portfolio Company ElastiMed Signs Exclusive U.S. Distribution Agreement with Nasdaq-Listed Tactile Medical for MyoSleeve™ Wearable Compression Device

- *This strategic distribution partnership brings ElastiMed's compression device for the treatment of venous and lymphatic conditions to ambulatory Veterans Affairs patients across the United States.*
- *This commercial agreement highlights Trendlines' portfolio strength and the attractiveness of its medical companies in the global market.*

Misgav, Israel, 14 July 2026 — The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, today announced that, further to its announcement from 18 May 2026, its portfolio company ElastiMed Ltd. ("**ElastiMed**"), a commercial-stage medical device company, pioneering the use of Electroactive Polymer (EAP) technology in wearable therapeutic devices, has entered into an exclusive U.S. distribution agreement with Tactile Systems Technology, Inc. ("**Tactile Medical**"), a Nasdaq-listed medical technology company (Nasdaq: TCMD). Under the agreement, Tactile Medical will serve as ElastiMed's exclusive U.S. distribution partner to bring MyoSleeve™, a discreet, wearable non-pneumatic compression device for the lower leg, to Department of Veterans Affairs ("**VA**") and Department of Defense ("**DoD**") patients at select VA and DoD facilities across the United States ("**U.S.**").

The agreement marks a major milestone in ElastiMed's U.S. commercial launch strategy, providing immediate access to a large, underserved patient population.

ElastiMed's MyoSleeve combines clinical-grade compression with comfort and connectivity in a breakthrough, low-profile wearable device, intended to promote compliance and support optimal clinical outcomes for the treatment of venous and lymphatic conditions.

"Partnering with Tactile Medical gives MyoSleeve a direct path to patients with chronic swelling who want to stay active while getting the treatment they need," said Omer Zelka, Chief Executive Officer of ElastiMed. "It is the first ambulatory all-in-one, cable-free, clinical-grade solution for patients with venous and lymphatic conditions. This partnership enables the first commercial introduction of MyoSleeve through a trusted and market-leading medical device partner, with the infrastructure and scale to make a meaningful impact."

"This distribution agreement is the kind of validation event that can change the trajectory of a company," said Dr. Amir Belson, ElastiMed's Chairman. "Tactile's reach and infrastructure, combined with the innovation behind MyoSleeve, put us in a strong position to bring meaningful relief to patients who have been underserved for too long."

"A commercial agreement with a Nasdaq-listed medical technology company is strong validation of ElastiMed's technology and of Trendlines' model of transforming early-stage innovations into commercial businesses, supporting long-term value creation for our shareholders," added Haim Brosh, CEO of The Trendlines Group.

About ElastiMed
ElastiMed Ltd. is a medical device company pioneering the use of Electroactive Polymer (EAP) technology in wearable therapeutic devices. Founded in 2015, the company has developed MyoSleeve - an FDA-cleared wearable compression device for the treatment of venous and lymphatic conditions. MyoSleeve delivers active, programmable compression through a soft, portable sleeve, offering a fundamentally different approach to a market long dominated by stationary compression garments.

About The Trendlines Group Ltd.
The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

----

*This press release has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, , #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg*.*

Investor Contact Information
Israel:
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore:
Kamal Samuel, Financial PR
kamal@financialpr.com.sg
Rishika Tiwari, Financial PR
rishika@financialpr.com.sg
Tel: +65.6438.2990